Phase 2 results (48 weeks): 1mg dose: 8.7% average weight loss 4mg dose: 17.1% average weight loss 8mg dose: 22.8% average weight loss 12mg dose: 24.2% average weight loss Placebo: 2.1% average weight loss These numbers came from a 48-week study period, six months shorter than the 72-week SURMOUNT trials
How do you know if Semaglutide GLP-1 is working
doi:10.1111/andr.12191
These findings underscore the multifaceted roles of DPP-4, not only as an osteoclast-derived protein but also as a connector between bone remodeling and energy metabolism, with significant implications for the pancreatic-endocrine-bone axis [3, 36, 37]
Contributing Researchers Recognized for published work that shaped the scientific context discussed above Jesper Lau, PhD led the discovery and medicinal-chemistry work describing the once-weekly GLP-1 analogue semaglutide ( Journal of Medicinal Chemistry , 2015) [2]
Learn more in the 2025 Employer Health Benefits Survey: To view or add a comment, sign in More Relevant Posts Will the White Houses recent deals to lower GLP-1 pricing impact employer health plans